Gefitinib is tyrosine kinase inhibitor of epidermal growth factor receptor, which exhibits
notable clinical efficacy in non-small-cell lung cancer (NSCLC) treatment. However, gefitinib …

Resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such
as gefitinib, has greatly affected clinical outcomes in non-small cell lung cancer (NSCLC) …

Long noncoding RNAs (lncRNAs) play crucial roles in the acquired resistance to EGFR-
directed therapies in lung cancer. LncRNA OSER1-AS1 has been reported to promote …

Background Chemoresistance is a major obstacle for chemotherapy failure in non-small-cell
lung cancer (NSCLC). lncRNAs are a class of pivotal regulators in various cancers, and the …

Abstract Background Long non-coding RNAs (lncRNAs) are extensively intricate in the
tumorigenesis and metastasis of various cancer types. Nevertheless, the detailed molecular …

Long non-coding RNA (lncRNA) colon cancer-associated transcript-1 (CCAT1) has been
reported to play important roles in the development and progression of multiple human …

The non–small cell lung cancer (NSCLC) patients harbor mutations in the epidermal growth
factor receptor (EGFR) can be therapeutically targeted by EGFR tyrosine kinase inhibitors …

Introduction Non-small cell lung cancer (NSCLC) is a deadly cancer type worldwide and the
main sub-type of lung cancer. Cancer susceptibility candidate-9 (CASC9) was reported to be …

In a meta-analysis, the long noncoding RNA cancer susceptibility candidate 8 (CASC8) was
found to be a cancer susceptibility gene closely related to lung cancer, but its functions in …

An increasing number of studies have indicated that long noncoding RNAs (lncRNAs) are
involved in the regulation of non-small-cell lung cancer (NSCLC). Nevertheless, there are …